Sarepta Therapeutics, Inc.
215 First Street
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy(DMD), Limb-girdle muscular dystrophy (LGMD) and CNS. The Company has close to 30 programs in development across several therapeutic modalities, including RNA, gene therapy and gene editing.
Corporate Mission Statement:
Armed with the most advanced science in genetic medicine, we are in a daily race to rescue lives otherwise stolen by rare disease.
At Sarepta, every day is another 24 hours to stand up for patients, advance technology, challenge convention and drag tomorrow into today.
754 articles with Sarepta Therapeutics, Inc.
Increased Defense-Related Funding Of AVI BioPharma Approved; $11 Million Allocated For Development Of Therapeutics For Ebola, Marburg And Dengue Viruses, And For Countermeasures For Anthrax And Ricin Toxins
AVI BioPharma, Inc. To Testify Before Congressional Committee On Bioterrorism Research And Development
AVI BioPharma, Inc. (AVII) Announces Positive Results In NEUGENE Antisense Studies With Collaborators Targeting Emerging Viral Diseases
AVI BioPharma And USAMRIID Announce NEUGENE Antisense Drug Demonstrates Efficacy Against Ebola Virus